IC3试验:在澳大利亚全科诊所中比较肝硬化检测与肝细胞癌监测路径与常规护理的多中心个体随机对照试验方案,受试者为45-75岁慢性肝病风险人群
该方案为前瞻性多中心平行随机对照试验,纳入2470名45-75岁慢性肝病风险者,1:1随机分入肝硬化检测路径组或常规全科医生护理组,主要结局为12个月时新诊断肝硬化并纳入肝细胞癌监测的比例组间差异,同时评估成本效果与实施障碍。
要点
- 在澳大利亚四州城乡全科诊所招募2470名45-75岁慢性肝病风险者,1:1随机分组。
- 干预组接受肝纤维化血液检测(FIB-4与Hepascore),指标升高者行FibroScan肝硬度检测。
- 主要结局为12个月时新诊断肝硬化并处于肝细胞癌监测中的受试者比例组间差异。
核心结论
- 该试验将提供肝硬化检测路径在澳大利亚全科医疗环境中有效性和成本效果的证据,以指导早期识别并将患者适当纳入肝细胞癌监测项目,从而实现更早的肝细胞癌诊断和改善结局。
研究设计与样本
- 前瞻性多中心平行随机对照试验,纳入2470名45-75岁有慢性肝病风险因素的受试者,来自澳大利亚四个州的区域和城市全科诊所。
- 受试者按1:1随机分入常规全科医生护理(对照组)或肝硬化检测路径(干预组),按诊所和潜在有害饮酒进行分层。
主要发现
- 主要结局为12个月时新诊断肝硬化并处于肝细胞癌监测中的受试者比例组间差异。
- 12个月次要结局包括任何分期肝细胞癌诊断、晚期纤维化诊断、肝失代偿诊断的比例组间差异,以及平均焦虑状态和平均生活质量。
- 将通过链接州和国家卫生数据集确定肝硬化检测路径的成本效果。
- 过程评估将通过受试者访谈评估最佳肝硬化检测路径及其实施的障碍和促进因素。
关键数值与推荐
- 干预组肝硬化检测包括肝纤维化血液检测(包含纤维化-4指数和Hepascore),对肝纤维化血液标志物升高者行FibroScan肝硬度测量。
- FibroScan值升高的受试者将被推荐转诊至肝病专科评估,以确定是否需要肝细胞癌监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatocellular carcinoma (HCC) incidence and mortality rates are increasing at a greater pace than any other cancer in Australia. Cirrhosis is the major risk factor for HCC, and early detection of HCC through surveillance of people with cirrhosis can improve outcomes. However, cirrhosis is under-detected in primary care settings, with 60% of patients diagnosed with HCC having unrecognised cirrhosis and not found to be in a surveillance programme. Targeted screening of at-risk populations in primary care using noninvasive tests for liver fibrosis could lead to improved diagnosis of cirrhosis and increased participation in HCC surveillance programmes. METHODS: This is a prospective multicentre parallel randomised controlled trial of 2470 participants, to evaluate the impact of a cirrhosis detection and hepatocellular carcinoma surveillance pathway compared to usual care in 45-75 year olds, with risk factors for chronic liver disease, from regional and urban general practice clinics, across four Australian states. Participants will be randomised 1:1, to usual general practitioner care (control) or a cirrhosis detection pathway (intervention), stratified by clinic and potential hazardous drinking. The cirrhosis detection intervention consists of liver fibrosis blood tests (comprising the Fibrosis-4 Index and Hepascore) and a liver stiffness measurement conducted by FibroScan in those with elevated liver fibrosis blood markers. Participants with elevated FibroScan® values will be recommended for referral for hepatology assessment to determine the need for HCC surveillance. The primary outcome is the between-arm difference in proportion of participants with newly diagnosed cirrhosis in HCC surveillance at 12 months. Secondary outcomes at 12 months will include the between-arm difference in proportion of participants with a diagnosis of any stage HCC, diagnoses of advanced fibrosis and liver decompensation and mean anxiety state and mean quality of life. The cost-effectiveness of the cirrhosis detection pathway will be determined using data linkage to state and national health datasets. Process evaluation will involve assessment of the optimal cirrhosis detection pathway, along with the barriers and enablers of implementation of this pathway, assessed by participant interviews. DISCUSSION: This trial will provide evidence of the efficacy and cost-effectiveness of a cirrhosis detection pathway in Australian general practice settings. This will provide evidence to guide the early identification and appropriate placement of patients in HCC surveillance programmes, resulting in earlier HCC diagnosis and improved outcomes. TRIAL REGISTRATION: Australian and New Zealand Clinical Trial Registry ACTRN12622000185763p. Registered on 3rd February 2022.
引用
- Adams LA, de Guingand D, Jeffrey GP, et al. The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75 years old with risk factors for chronic liver disease. Trials. 2025. PMID: 40993832. doi:10.1186/s13063-025-09037-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。